Atlas Trials

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Clinical trial NCT02650752 · COMPLETED

Trial details

NCT number
NCT02650752
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Breast CancerCentral Nervous System (CNS) Metastases
Start date
2016-01-06
Primary completion
2021-01-22
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.